Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore

Keeping Track Feature image

Related Content

Keeping Track: US FDA Receives Submissions Galore As Year Ends

Jan 07 2019

Keeping Track: Recarbrio Approval Highlights Two-Week Roundup

Jul 19 2019

Keeping Track Of The US FDA's Final Approvals Of 2018

Jan 03 2019

Endo’s Opana IR Should Not Add Pediatric Data To Labeling, US FDA Panel Says

Sep 27 2019

Opana IR Pediatric Labeling Supplement Faces US FDA Panel Review

Sep 25 2019

Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light

Sep 02 2019

US FDA's Temple On Real-World Evidence: 'I Find The Whole Thing Very Frustrating'

Oct 16 2019

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

Aug 12 2019

Keeping Track: A Quintet Of Novel Approvals

Aug 18 2019

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal

Mar 15 2019

Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA

Apr 06 2019

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Oct 01 2018

Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials

Apr 16 2019

What's Missing In Intellipharmaceutics' Opioid Filing? FDA Panel Offers List

Jul 30 2017

Purdue Butrans Pediatric Study Added To Label – Sort Of

Oct 20 2017

Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews

Oct 02 2017

A Baker’s Dozen Of US FDA Efficacy Approvals Using Real World Evidence

Aug 08 2018

Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

Jan 29 2019

Roche Mounts NMOSD Challenge To Alexion’s Soliris

Sep 12 2019

AstraZeneca Aiming To Extend Brilinta Use In PCI patients

Sep 02 2019

AZ/Merck & Co’s Lynparza POLO Study ‘Practice Changing’ For Pancreatic Cancer Subgroup

Jun 03 2019

Bile Duct Cancer Enters Targeted Therapy Era As Agios And Incyte Prepare Filings

Oct 03 2019

Shire's Alagille syndrome drug fails Phase II trial

Apr 09 2015

While You Were Out: News In Brief

Dec 31 2018

Newly Hatched Mirum To Focus On Rare Liver Disease Candidates Shelved By Shire

Nov 07 2018

Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

Jun 18 2019

Related Companies

MorphoSys AG

Incyte Corporation

Omeros Corporation

Akari Therapeutics, Plc

Roche Holding AG

Alexion Pharmaceuticals Inc.

Chugai Pharmaceutical Co., Ltd.

Pfizer Inc.

Array BioPharma, Inc.

AstraZeneca PLC

Spectrum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

Albireo Pharma Inc.

Merck & Co., Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Intellipharmaceutics International Inc.

Endo, Inc.

Purdue Pharma L.P.

Johnson & Johnson

Viela Bio, Inc.

Nektar Therapeutics

Additional Topics

United States Drug Review Regulation US FDA Performance Tracker BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window